CD4 and neoplasm: Because we observed an increase in functional anti-tumor CD8 T cells (increased ratio of CD8: CD4, CD25) we interrogated if the combination of MSU42011 with anti-PD1 or anti-PDL1 antibodies would be beneficial in the A/J lung cancer model.